Annoucements Archives

DermaXon Partners with New York Based AI company VantAI For Two Drug Development Programs

DermaXon announces its partnership with VantAI, a Roivant Biosciences Vant company, for the rapid acceleration of two of its drug development programs. VantAI leads the computational drug discovery space with technology at the bleeding edge of machine learning and...

DermaXon will be presenting at BIO 2020, NIH Innovation Zone June 8 -12, 2020

Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke

September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...

DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis

MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.

Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke

June 2018: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain. This award titled “Topical selective T-type blockers for the...